APR 21, 2019 10:20 PM PDT

Type 2 Diabetic Drug Reverses Heart Failure

WRITTEN BY: Nouran Amin

In a study published in the Journal of American Cardiology, a drug used for the treatment of diabetes—empagliflozin—was shown to improve the hearts function by reversing the progression of heart failure in non-diabetic animal models.

"This drug could be a promising treatment for heart failure in both non-diabetic and diabetic patients," said lead author Juan Badimon, MD, Professor of Cardiology and Director of the Atherothrombosis Research Unit at the Cardiovascular Institute at the Icahn School of Medicine at Mount Sinai. "Our research can lead to a potential application in humans, save lives, and improve quality of life."

Learn more about how diabetes is related to heart disease:

In diabetes, empagliflozin limits renal sugar resorption in individuals with Type 2 diabetes. Past studies have confirmed that these patients that take empagliflozin don't commonly develop heart failure despite having a higher risk due to their diabetes. These studies led researchers to wonder if the drug exerts action independent of anti-diabetic activity that is implicated in heart failure prevention.

Researchers found that the drug reversed heart failure by improving cardiac metabolism—producing more energy and function more strongly and efficiently.

"This study confirmed our hypothesis that empagliflozin is an incredibly effective treatment for heart failure and not only an antidiabetic drug. Moreover, this study demonstrated that empagliflozin is useful for heart failure independently of a patient's diabetic status. Importantly, empagliflozin switches cardiac metabolism toward fatty acid and ketone body consumption, thus allowing the production of more energy in the heart," explained co-lead author Carlos Santos-Gallego, MD, postdoctoral fellow at the Icahn School of Medicine at Mount Sinai. "Empagliflozin may be a potentially effective treatment for heart failure patients. This is extremely important because heart failure is a disease with a mortality above 50 percent at 5 years. This study offers a new therapeutic strategy in heart failure, something badly needed given that there have not been new effective drugs for heart failure since the 1990s."

Source: Science Daily

About the Author
  • Nouran earned her BS and MS in Biology at IUPUI and currently shares her love of science by teaching. She enjoys writing on various topics as well including science & medicine, global health, and conservation biology. She hopes through her writing she can make science more engaging and communicable to the general public.
You May Also Like
APR 15, 2020
Chemistry & Physics
APR 15, 2020
Could this drug help people with SAD?
Have you ever been sad in the winter? If so, you’re not alone. Medaka fish feel it too. Seasonal affective disorde ...
APR 22, 2020
Drug Discovery & Development
APR 22, 2020
Only 3% of COVID-19 Antibody Tests Approved by FDA
So far, only 3% of at least 90 COVID-19 antibody tests in the US have been approved by the Food and Drug Administration ...
MAY 08, 2020
Drug Discovery & Development
MAY 08, 2020
Cholesterol Drugs May Boost Healthy Gut Bacteria in Obese People
While statins have long been known for their efficacy in treating high cholesterol, until recently, there was no evidenc ...
MAY 06, 2020
Cancer
MAY 06, 2020
Olanzapine useful for cancer patients managing nausea unrelated to chemo
A study published last week in JAMA Oncology reports that a generic drug called Olanzapine could be useful for cancer pa ...
MAY 16, 2020
Cancer
MAY 16, 2020
Red Blood Cells: More than just an Oxygen Delivery Service
The human body is a complex network of systems that often interact and affect each other. Recent work shows that red blo ...
MAY 21, 2020
Cancer
MAY 21, 2020
A New Player in the Regulation of Cancer's Microenvironment
Breast cancer is one of the most common cancers in the world.  Triple-negative breast cancer (TNBC) is a sub-type o ...
Loading Comments...